Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - Frequency Therapeutics, Inc. | freq-ex312_22.htm |
EX-32.1 - EX-32.1 - Frequency Therapeutics, Inc. | freq-ex321_8.htm |
EX-31.1 - EX-31.1 - Frequency Therapeutics, Inc. | freq-ex311_16.htm |
EX-23.1 - EX-23.1 - Frequency Therapeutics, Inc. | freq-ex231_7.htm |
EX-21.1 - EX-21.1 - Frequency Therapeutics, Inc. | freq-ex211_19.htm |
EX-10.16 - EX-10.16 - Frequency Therapeutics, Inc. | freq-ex1016_1057.htm |
10-K - 10-K - Frequency Therapeutics, Inc. | freq-10k_20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Frequency Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Pfreundschuh, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: March 29, 2021 |
|
By: |
/s/ Peter Pfreundschuh |
|
|
|
Peter Pfreundschuh |
|
|
|
Chief Financial Officer |